WMSA
BMRN icon

Weiss Multi-Strategy Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,000
Closed -$878K – 527
2017
Q1 		$878K Buy
+10,000
New +$890K 0.03% 402

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Weiss Multi-Strategy Advisers's BMRN Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 35,955 shares — an estimated $3.47M sold.

Weiss Multi-Strategy Advisers first reported a position in BMRN in Q2 2013 and held it in 43 quarters. The position peaked at $9.03M in Q2 2015. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 35,955 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $3.47M.
  • Weiss Multi-Strategy Advisers first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 43 quarters.
  • Weiss Multi-Strategy Advisers's BioMarin Pharmaceuticals position peaked at $9.03M in Q2 2015.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.